Noteworthy Form D Filing: Cure Pharmaceutical $323212 Fundraising. Mark Udell Released Oct 31 D form

Pharmaceuticals Cure Pharmaceutical Corp - Mark Udell

Cure Pharmaceutical Financing

Cure Pharmaceutical Corp, Corporation just submitted form D regarding $323,212 debt financing. This is a new filing. Cure Pharmaceutical was able to sell $323,212. That is 100.00% of the fundraising offer. The total private financing amount was $323,212. This form was filed on 2016-10-31. The reason for the financing was: unspecified.

Cure Pharmaceutical is based in California. The company’s business is Pharmaceuticals. The SEC form was submitted by Mark Udell CFO. The company was incorporated more than five years ago. The filler’s address is: 1620 Beacon Place, Oxnard, Ca, California, 93033. Rob Davidson is the related person in the form and it has address: 1620 Beacon Place, Oxnard, Ca, California, 93033. Link to Cure Pharmaceutical Filing: 000155428916000006.

Analysis of Cure Pharmaceutical Offering

On average, firms in the Pharmaceuticals sector, sell 60.90% of the total offering size. Cure Pharmaceutical sold 100.00% of the offering. Could this mean that the trust in Cure Pharmaceutical is high? The average financing size for companies in the Pharmaceuticals industry is $556,000. The offering was 41.87% smaller than the average of $556,000. Of course this should not be seen as negative. Businesses raise funds for a variety of needs and reasons. The minimum investment for this financing is set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Cure Pharmaceutical Also

The Form D signed by Mark Udell might help Cure Pharmaceutical Corp’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Related posts

Leave a Comment